ALL MARKETS
FTSE 100
FTSE 250
AIM MARKET


NOVARTIS AG CHF0.50.
52 announcements.
Time Date Ticker Company Announcement
06:15 23-09-2020 0QLR NOVARTIS AG CHF0.50
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
06:15 14-09-2020 0QLR NOVARTIS AG CHF0.50
Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
06:15 08-09-2020 0QLR NOVARTIS AG CHF0.50
Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum
06:15 07-09-2020 0QLR NOVARTIS AG CHF0.50
Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
06:00 01-09-2020 0QLR NOVARTIS AG CHF0.50
Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality
06:15 26-08-2020 0QLR NOVARTIS AG CHF0.50
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
06:15 04-08-2020 0QLR NOVARTIS AG CHF0.50
Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
06:15 03-08-2020 0QLR NOVARTIS AG CHF0.50
Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis
06:00 21-07-2020 0QLR NOVARTIS AG CHF0.50
Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.
06:15 16-07-2020 0QLR NOVARTIS AG CHF0.50
Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
06:15 07-07-2020 0QLR NOVARTIS AG CHF0.50
Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
07:45 29-06-2020 0QLR NOVARTIS AG CHF0.50
Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
00:13 17-06-2020 0QLR NOVARTIS AG CHF0.50
Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
06:15 11-06-2020 0QLR NOVARTIS AG CHF0.50
US FDA approves updated Novartis Beovu® label, to include additional safety information
06:15 05-06-2020 0QLR NOVARTIS AG CHF0.50
Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
06:15 04-06-2020 0QLR NOVARTIS AG CHF0.50
Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis
06:15 27-05-2020 0QLR NOVARTIS AG CHF0.50
Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)
06:17 27-05-2020 0QLR NOVARTIS AG CHF0.50
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
06:15 19-05-2020 0QLR NOVARTIS AG CHF0.50
AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
06:15 01-05-2020 0QLR NOVARTIS AG CHF0.50
Novartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma
06:15 29-04-2020 0QLR NOVARTIS AG CHF0.50
Novartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum
06:00 28-04-2020 0QLR NOVARTIS AG CHF0.50
Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19
06:15 22-04-2020 0QLR NOVARTIS AG CHF0.50
Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
06:15 21-04-2020 0QLR NOVARTIS AG CHF0.50
Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)
06:17 20-04-2020 0QLR NOVARTIS AG CHF0.50
Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”
06:32 20-04-2020 0QLR NOVARTIS AG CHF0.50
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients
06:15 16-04-2020 0QLR NOVARTIS AG CHF0.50
Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine
03:00 02-04-2020 0QLR NOVARTIS AG CHF0.50
Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo
06:15 26-03-2020 0QLR NOVARTIS AG CHF0.50
Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic alongside Bill & Melinda Gates Foundation
06:15 24-02-2020 0QLR NOVARTIS AG CHF0.50
Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)
06:15 11-02-2020 0QLR NOVARTIS AG CHF0.50
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
06:30 31-01-2020 0QLR NOVARTIS AG CHF0.50
Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines
06:00 29-01-2020 0QLR NOVARTIS AG CHF0.50
Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
08:00 16-01-2020 0QLR NOVARTIS AG CHF0.50
Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People
06:00 06-01-2020 0QLR NOVARTIS AG CHF0.50
Novartis completes tender offer for all outstanding shares of The Medicines Company
06:15 16-12-2019 0QLR NOVARTIS AG CHF0.50
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
06:15 06-12-2019 0QLR NOVARTIS AG CHF0.50
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
06:00 05-12-2019 0QLR NOVARTIS AG CHF0.50
Novartis tender offer for The Medicines Company commences
06:15 05-12-2019 0QLR NOVARTIS AG CHF0.50
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day
06:15 12-11-2019 0QLR NOVARTIS AG CHF0.50
New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis
06:25 12-11-2019 0QLR NOVARTIS AG CHF0.50
Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment
06:00 11-11-2019 0QLR NOVARTIS AG CHF0.50
Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market
06:15 05-11-2019 0QLR NOVARTIS AG CHF0.50
Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez)
06:15 01-11-2019 0QLR NOVARTIS AG CHF0.50
Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
06:00 30-10-2019 0QLR NOVARTIS AG CHF0.50
Novartis announces AVXS-101 intrathecal study update
06:15 24-10-2019 0QLR NOVARTIS AG CHF0.50
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis
06:00 22-10-2019 0QLR NOVARTIS AG CHF0.50
Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
06:15 08-10-2019 0QLR NOVARTIS AG CHF0.50
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
06:15 08-10-2019 0QLR NOVARTIS AG CHF0.50
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
06:15 02-10-2019 0QLR NOVARTIS AG CHF0.50
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
08:00 19-09-2019 0QLR NOVARTIS AG CHF0.50
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
06:15 17-09-2019 0QLR NOVARTIS AG CHF0.50
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis